Amarin Corp. Plc Q3 FY2026 earnings call

• Financial Turnaround: Ameren recorded its first profitable quarter in two years, with net income of $245,000 (less than $0.01 per share) compared to a net loss of $7.7 million in the prior year period.
• Cash Position: The company generated positive operating cash flow of $9 million in Q3 2026, contributing to $22 million in cumulative operating cash flow for the first nine months of 2026. The balance sheet ended with $324 million in cash and investments, remaining debt-free.
• Cost Structure Reduction: Total operating expenses declined by 44% year-over-year, driven by a 27% reduction in SG&A and the absence of restructuring expenses. Excluding restructuring costs, operating expenses declined by 22%, establishing a significantly lower go-forward cost base.
• Gross Margin Improvement: Cost of goods sold decreased to $23.4 million from $27.5 million. Sequential gross margin improved by approximately 2.3 percentage points, excluding write-offs, due to renegotiated supply contracts and favorable API purchase timing.
• Inventory Optimization: Inventory levels have declined by 31% from Q4 2024, reflecting disciplined working capital management and alignment of supply with demand.
• International Growth Momentum: In-market demand for VASCEPA/SEPA rose by an estimated 68% in Europe and 46% in the Rest of the World compared to Q3 2025. Combined global in-market demand increased by an estimated 55%. The partnership with Recordati has expanded commercialization to 11 countries in Europe, with a recent launch in Poland.
• U.S. Market Leadership: Ameren maintained a leading position in the U.S. IPE market with a 47% share. Despite pricing pressure from generics, volume remained stable, and the company expects to maintain exclusivity with key payers through the end of 2026.
• Scientific Advancements: The company highlighted results from the EMT2 Phase 3 trial, which showed a statistically significant 32% reduction in the hazard of death (overall survival benefit) in colorectal cancer patients, although the primary endpoint of progression-free survival was not met. Additionally, Icosapent Ethyl was included in new European guidelines for cardiovascular and chronic kidney disease management.

• Total Net Revenue: $39.6 million (down from $49.7 million in Q3 2025). This represents a decrease of approximately 20% year-over-year.
• Product Revenue: $36.9 million (down from $48.6 million in Q3 2025).
  • U.S. Product Revenue: $28.5 million (down from $40.9 million in Q3 2025), driven by lower net selling prices due to generic competition and customer mix changes, despite stable volumes.
  • Europe Product Revenue: $3.7 million (down from $4.1 million in Q3 2025), reflecting partner inventory ordering patterns despite strong in-market demand growth.
  • Rest of the World Product Revenue: $4.7 million (up from $3.6 million in Q3 2025), supported by continued commercial investment and execution.
• Licensing and Royalty Revenue: $2.7 million (up from $1.1 million in Q3 2025).
• Revenue Contribution: The U.S. market remains the primary revenue driver, accounting for approximately 72% of total product revenue ($28.5M of $36.9M), while international markets (Europe and Rest of World) contribute the remaining 28%, though they are experiencing faster underlying demand growth.

• Full-Year Outlook: Management maintains a positive outlook for the full year 2026, expecting continued positive operating cash flow.
• U.S. Pricing and Exclusivity: Expectations are that U.S. pricing will remain relatively consistent through the end of 2026, supported by maintained exclusivity with key payers. However, management anticipates continued pricing pressure into 2027 as final confirmation on exclusivity structures is pending.
• U.S. Volumes: U.S. volumes are expected to remain stable through the end of 2026. Changes in product exclusivity are considered part of the normal cadence of the U.S. commercial business.
• International Revenue Timing: While international in-market demand is growing rapidly (estimated 59% increase over the trailing 12 months), management cautions that international product revenue may not grow at the same rate in any single quarter due to partner inventory levels and ordering patterns. A trailing 12-month view is recommended for evaluating international performance.
• Cost Base: The significantly lower go-forward cost structure established through restructuring is intended to be maintained through continued spending discipline.

• U.S. Pricing Pressure: Continued downward pressure on net selling prices in the U.S. due to generic competition and changes in customer mix poses a risk to revenue growth, even if volumes remain stable.
• International Revenue Recognition Lag: There is a potential mismatch between rapid growth in in-market demand and quarterly product revenue recognition, as international revenue depends on partner supply purchases which can vary quarter-to-quarter based on inventory levels.
• Clinical Trial Outcomes: The EMT2 trial did not meet its primary endpoint of progression-free survival, representing a partial failure in expanding the indication to oncology. Further evaluation is required to understand the overall survival benefit and determine future strategic directions.
• Regulatory and Reimbursement Uncertainty: Success in expanding international footprint, particularly in major markets like France, depends on lengthy and uncertain reimbursement and regulatory processes.
• Strategic M&A/Transaction Risks: Discussions with Barclays regarding potential corporate actions (such as share repurchases or other capital deployment) introduce uncertainty regarding timing, scale, and prioritization of future activities.

Q: Jessica Fye (JP Morgan) asked how to reconcile stable branded prescription volume growth with the decline in U.S. revenues, and sought clarity on the U.S. price trajectory.

A: Aaron Berg clarified that branded VASCEPA volume was flat/stable, attributing the revenue decline entirely to pricing pressure from generic competition. Pete Fishman added that U.S. pricing is expected to remain relatively consistent through the end of 2026 due to maintained payer exclusivities. However, he noted that continued pricing pressure is anticipated into 2027, as the company awaits final confirmation on how exclusivity structures will look beyond the current year.

Q: Paul Choi (Goldman Sachs) inquired about updates on reimbursement and coverage in major European markets and asked about criteria for additional therapeutic applications, including potential co-funding partnerships.

A: Aaron Berg highlighted that partner Recordati is executing aggressively across 59 countries, launching in new markets like Poland and exploring entry into France, surpassing what Ameren could achieve independently. Regarding new indications like oncology (EMT2 trial), Berg stated the company will assess commercial opportunity, unmet need, and data protection before deciding on a path. He emphasized a disciplined approach to risk and indicated that while they are collaborating with academic investigators, any future development would require careful assessment of commercial viability and potential partner structures.

Q: Implicit in the Q&A, analysts focused on the disconnect between strong international demand metrics and lagging international revenue recognition.

A: CFO Pete Fishman explained that while in-market demand grew ~68% in Europe and ~46% globally, partner supply purchases (which drive revenue) vary based on inventory levels and ordering patterns. He advised investors to use a trailing 12-month view to better evaluate international revenue trends, as quarterly fluctuations in partner orders may not immediately reflect underlying demand growth. This highlights a structural shift where revenue recognition is increasingly dependent on partner logistics rather than direct sales velocity.